UHealth - University of Miami Health System

Mingjiang Xu

General Information

Mingjiang  Xu


  • .(JavaScript must be enabled to view this email address)


  • English


  • Associate Professor of Biochemistry and Molecular Biology


Research Interests

  • Roles of TET2 and PHF6 mutations in the pathogenesis of hematological malignancies
  • Roles of SETBP1 mutations in the pathogenesis of myeloid malignancies
  • Roles of TET1 in the pathogenesis of hematological malignancies
  • Development of novel therapeutics for hematological malignancies


Showalter Scholar, Indiana University School of Medicine


2001 PhD
University of Tokyo
1994 MD
Shandong University School of Medicine


  • 1. Zhao Z, Chen S, Zhu X, Pan F, Li R, Zhou Y, Yuan W, Ni H, Yang F-C, Xu M. The catalytic activity of TET2 is essential for its myeloid malignancy-suppressive function in hematopoietic stem/progenitor cells. Leukemia (2016) In press
  • 2. Zhao Z, Chen L, Dawlaty M, Pan F, Weeks O, Zhou Y, Cao Z, Shi H, Wang J, Li L, Chen S, Yuan W, Qin Z, Ni H, Nimer SD, Yang F-C, Jaenisch R, Jin P, Xu M. Combined loss of Tet1 and Tet2 promotes B-cell, but not myeloid malignancies in mice. Cell Reports 2015 Nov. 24; 13(8):1692–1704.
  • 4. Wang J, Li Z, He Y, Pan F, Chen S, Rhodes SD, Nguyen L, Yuan J, Yang X, Jiang L, Weeks O, Liu Z, Zhou J, Ni H, Cai C-L, Xu M, Yang F-C. Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. Blood 123:541-553, (2014).
  • 5. Huang H, Jiang X, Li Z, Li Y, Song C, He C, Sun M, Chen P, Gurbuxani S, Wang J, Hong G-M, Elkahloun AG, Arnovitz S, Wang J, Szulwach K, L Li, Street C, Wunderlich M, Dawlaty M, Neilly MB, Jaenisch R, Yang F-C, Mulloy JC, Jin P, Liu P, Rowley JD, Xu M, He C, Chen J. TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci USA 16;110:11994-9, (2013).
  • 6. Costa Y, Ding J, Theunissen T, Faiola F, Hore T, Shliaha P, Fidalgo M, Saunders A, Lawrence M, Dietmann S, Das S, Levasseur D, Li Z, Xu M, Reik W, Silva JCR, Wang J. Nanog-dependent function of Tet1 and Tet2 in establishment of pluripotency. Nature 21;495:370-4, (2013).
  • 7. Dawlaty M, Breiling A, Le T, Raddatz G, Barrasa MI, Cheng A, Gao Q, Powell B, Li Z, Xu M, Faull KF, Lyko F, and Jaenisch R. Combined deficiency of Tet1 and Tet2 causes epigenetic abnormalities but is compatible with postnatal development. Developmental Cell 24:310-323, (2013).
  • 8. Bocker MT, Tuorto F, Raddatz G, Musch T, Yang F-C, Xu M, Lyko F, Breiling A. Hydroxylation of 5-methylcytosine by TET2 maintains the active state of the mammalian HOXA cluster. Nature Communications 3: 818, (2012).
  • 9. Li Z, Cai X, Cai C, Zhang W, Wang J, Petersen B, Yang F-C, and Xu M. Deletion of Tet2 in Mice Leads to Dysregulated Hematopoietic Stem Cells and Subsequent Development of Myeloid Malignancies. Blood 118:4509-18, (2011).
  • PubMed


 Dr. Xu is a well establish scientist in the field of epigenetics and hematological malignancies. Dr. Xu has been investigating the cellular, epigenetic and molecular mechanisms underlying the pathogenesis of hematological malignancies by focusing on several patient-derived gene mutations implicated in epigenetic regulation and dys-regulated long noncoding RNAs. His ultimate goal is to identify novel therapeutic targets/strategies and to develop effective therapies for hematological malignancies. He has authored over 70 peer-reviewed papers in this field of research.

Dr. Xu started his independent career as an Assistant Professor at Mount Sinai School of Medicine, New York, then as an Associate Professor at Indiana University School of Medicine, Indianapolis. In March 2015, he moved to University of Miami Miller School of Medicine as an Associate Professor in the Department of Biochemistry & Molecular Biology and Sylvester Comprehensive Cancer Center.

Dr. Xu is a member of several professional societies and serves on the review boards for a number of professional journals and funding agencies.